NEW YORK (Dow Jones)--Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in children with bipolar disorder, a controversial area for the drug.
UPDATE:Pfizer Ends Pediatric Bipolar-Drug Trial Before It Starts
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment